{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:32:56Z","timestamp":1707525176141},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,28]]},"DOI":"10.7759\/cureus.41087","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T15:16:44Z","timestamp":1687965404000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-Induced Myasthenia Gravis: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Buse","family":"Eglenen Polat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danish","family":"Safi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Hafez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy","volume":"152","author":"Duong SL","year":"2021","unstructured":"Duong SL, Barbiero FJ, Nowak RJ, Baehring JM. Neurotoxicities associated with immune checkpoint inhibitor therapy. J Neurooncol. 2021, 152:265-77. 10.1007\/s11060-021-03695-w","journal-title":"J Neurooncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh AM","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020, 19:479-88. 10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170219","article-title":"Severe exacerbation of myasthenia gravis associated with checkpoint inhibitor immunotherapy","volume":"4","author":"Cooper DS","year":"2017","unstructured":"Cooper DS, Meriggioli MN, Bonomi PD, Malik R. Severe exacerbation of myasthenia gravis associated with checkpoint inhibitor immunotherapy. J Neuromuscul Dis. 2017, 4:169-73. 10.3233\/JND-170219","journal-title":"J Neuromuscul Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100317","article-title":"How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors","volume":"6","author":"Jordan B","year":"2021","unstructured":"Jordan B, Benesova K, Hassel JC, Wick W, Jordan K. How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. ESMO Open. 2021, 6:100317. 10.1016\/j.esmoop.2021.100317","journal-title":"ESMO Open"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon AC","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK, et al.. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021, 9:10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-021-02722-8","article-title":"Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report","volume":"15","author":"Tian CY","year":"2021","unstructured":"Tian CY, Ou YH, Chang SL, Lin CM. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report. J Med Case Rep. 2021, 15:244. 10.1186\/s13256-021-02722-8","journal-title":"J Med Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious D","year":"2017","unstructured":"Makarious D, Horwood K, Coward JI. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017, 82:128-36. 10.1016\/j.ejca.2017.05.041","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.355","article-title":"Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer","volume":"6","author":"Hibino M","year":"2018","unstructured":"Hibino M, Maeda K, Horiuchi S, Fukuda M, Kondo T. Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer. Respirol Case Rep. 2018, 6:e00355. 10.1002\/rcr2.355","journal-title":"Respirol Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25496","article-title":"A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma","volume":"55","author":"Alnahhas I","year":"2017","unstructured":"Alnahhas I, Wong J. A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma. Muscle Nerve. 2017, 55:E25-6. 10.1002\/mus.25496","journal-title":"Muscle Nerve"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2018.14.1.115","article-title":"Emergence of myasthenia gravis with myositis in a patient treated with pembrolizumab for thymic cancer","volume":"14","author":"Huh SY","year":"2018","unstructured":"Huh SY, Shin SH, Kim MK, Lee SY, Son KH, Shin HY. Emergence of myasthenia gravis with myositis in a patient treated with pembrolizumab for thymic cancer. J Clin Neurol. 2018, 14:115-7. 10.3988\/jcn.2018.14.1.115","journal-title":"J Clin Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: new case and literature review","volume":"27","author":"Gonzalez NL","year":"2017","unstructured":"Gonzalez NL, Puwanant A, Lu A, Marks SM, \u017divkovi\u0107 SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017, 27:266-8. 10.1016\/j.nmd.2017.01.002","journal-title":"Neuromuscul Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-21-147","article-title":"Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report","volume":"11","author":"Portol\u00e9s Hern\u00e1ndez A","year":"2021","unstructured":"Portol\u00e9s Hern\u00e1ndez A, Blanco Clemente M, Escribano Garc\u00eda D, et al.. Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report. Cardiovasc Diagn Ther. 2021, 11:1013-9. 10.21037\/cdt-21-147","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16316","article-title":"Myasthenia gravis as an immune-mediated side effect of checkpoint inhibitors","volume":"13","author":"Heleno CT","year":"2021","unstructured":"Heleno CT, Mustafa A, Gotera NA, Tesar A. Myasthenia gravis as an immune-mediated side effect of checkpoint inhibitors. Cureus. 2021, 13:e16316. 10.7759\/cureus.16316","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126246","article-title":"Myositis\/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: immune-biological evaluation and case report","volume":"22","author":"Botta C","year":"2021","unstructured":"Botta C, Agostino RM, Dattola V, et al.. Myositis\/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: immune-biological evaluation and case report. Int J Mol Sci. 2021, 22:10.3390\/ijms22126246","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2021.46","article-title":"Multiple immune-related adverse event overlap in two patients treated with pembrolizumab","volume":"49","author":"Jenkins JD","year":"2022","unstructured":"Jenkins JD, Camara-Lemarroy C, Joseph JT, Brust T. Multiple immune-related adverse event overlap in two patients treated with pembrolizumab. Can J Neurol Sci. 2022, 49:133-5. 10.1017\/cjn.2021.46","journal-title":"Can J Neurol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytaa051","article-title":"Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent\/metastatic thymic carcinoma patient: a case report","volume":"4","author":"Szuchan C","year":"2020","unstructured":"Szuchan C, Elson L, Alley E, et al.. Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent\/metastatic thymic carcinoma patient: a case report. Eur Heart J Case Rep. 2020, 4:1-8. 10.1093\/ehjcr\/ytaa051","journal-title":"Eur Heart J Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-020-00408-4","article-title":"Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma","volume":"9","author":"Hayakawa N","year":"2020","unstructured":"Hayakawa N, Kikuchi E, Suzuki S, Oya M. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma. Int Cancer Conf J. 2020, 9:123-6. 10.1007\/s13691-020-00408-4","journal-title":"Int Cancer Conf J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.04.007","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis in a patient with advanced NSCLC and remote history of thymoma","volume":"20","author":"Lara MS","year":"2019","unstructured":"Lara MS, Afify A, Ellis MP, Phan CT, Richman DP, Riess JW. Immune checkpoint inhibitor-induced myasthenia gravis in a patient with advanced NSCLC and remote history of thymoma. Clin Lung Cancer. 2019, 20:e489-91. 10.1016\/j.cllc.2019.04.007","journal-title":"Clin Lung Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/162465-pembrolizumab-induced-myasthenia-gravis-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:34Z","timestamp":1707508834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/162465-pembrolizumab-induced-myasthenia-gravis-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.41087","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,28]]}}}